Could your own immune cells fight lung cancer? new trial tests safety
NCT ID NCT07498439
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will test whether infusing a patient's own tumor-fighting immune cells (called TILs) is safe for people with early-stage non-small cell lung cancer that has multiple spots in the lungs. Researchers will collect immune cells from the tumor or lung fluid, grow them in a lab, and give them back to the patient. The main goal is to check for side effects, not yet to see if it works. Fifty adults aged 18 to 75 with confirmed multiple lung nodules will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tumor-infiltrating lymphocytes (TILs) - immune cells taken from the patient's own tumor or lung fluid, grown in a lab, and given back as an infusion
- What this could lead to
- If this treatment is safe, it could point toward a new way to control early-stage lung cancer using the body's own immune cells.
- What could go wrong
- This is a very early, small safety study, so it is not designed to prove the treatment works. There may be side effects from the infusion, and the approach may not shrink tumors or prevent cancer from coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY EARLY-STAGE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.